[Randomized crossover trial of the antiemetic effects obtained with metoclopramide and droperidol versus those obtained with metoclopramide, droperidol and methylprednisolone in patients receiving cis-platinum chemotherapy].
Twenty-four patients with lung cancer receiving cis-platinum chemotherapy were entered in an antiemetic randomized crossover trial. The effects of high-dose metoclopramide and droperidol (regimen I) were compared with those obtained with a combination of high-dose metoclopramide, droperidol and methylprednisolone (regimen II). Three patients (12.5%) treated with regimen I and 10 (43.5%) treated with regimen II had no vomiting at all (p less than 0.05). Patient preference was significantly in favor of regimen II (p less than 0.05). No Severe side effects were observed. A further trial is necessary to determine the optimal dosage and scheduling of the available agents.
D000368:Aged; D002945:Cisplatin / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004329:Droperidol / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008787:Metoclopramide / Q000008:administration & dosage*; D008875:Middle Aged; D009325:Nausea / Q000188:drug therapy* / Q000517:prevention & control; D011897:Random Allocation; D014839:Vomiting / Q000188:drug therapy / Q000517:prevention & control
D008787:Metoclopramide; D004329:Droperidol; D002945:Cisplatin; D008775:Methylprednisolone